1. Scrip
  3. >>Anticancer

Spectrum regains apaziquone from Allergan, to file US NDA on pooled data

 
• By Mandy Jackson

Spectrum Pharmaceuticals has reacquired the rights to apaziquone from Allergan, but the company's stock price likely rose higher on 31 January due to Spectrum's announcement that the US FDA will allow submission of a new drug application (NDA) based on statistically significant results in a pooled data analysis from two failed Phase III bladder cancer studies.

Spectrum Pharmaceuticals has reacquired the rights to apaziquone from Allergan, but the company's stock price likely rose higher on 31 January due to Spectrum's announcement that the US FDA will allow submission of a new drug application (NDA) based on statistically significant results in a pooled data analysis from two failed Phase III bladder cancer studies.

Spectrum's stock ended the day up $0.68, or 5.7%, at $12.61 per share, which is between the low-end and mid-point of its range for the past year: $9.31-17.48. The Henderson,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Therapeutic Category